Young Jonathan

COO Young Jonathan sold 12,500 shares at blended average $47.76 on 2025-10-01, reducing holdings by 6.0%; stock now -19.9% from 52-week high.

Jonathan Young, Chief Operating Officer, executed 2 separate sales totaling 12,500 shares for $596,978.34 on 2025-10-01, leaving him with 196,898 shares post-transaction. The sale occurred near the 52-week high ($47.64 and $47.98 are close to the $57.56 peak), but the stock has since declined 19.9% to a current price of $46.10, suggesting the timing was favorable relative to subsequent price action. However, his cross-ticker track record shows prior open-market sells were poorly timed overall (90d average return +24.2% after sales, meaning the stock typically rose after he sold), and at AKRO specifically, the measurable same-ticker outcomes on prior sells have been mixed (30d returns ranging from -7.0% to +1.4%). The company remains unprofitable with net income of -$70,505,000.00, providing no fundamental tailwind to support the recent price decline. This sale reduces his stake by 6.0% and occurs in a stock environment where the long-term trend is downward despite a modest +1.0% 30-day bounce.

Akero Therapeutics COO Jonathan Young sold 12,500 shares for $576,035.08 on 2025-09-02; stock down 23.5% from 52-week high and -11.2% over 30 days.

Jonathan Young, Chief Operating Officer of Akero Therapeutics, executed 3 separate sales totaling 12,500 shares for $576,035.08 at prices ranging from $45.78 to $47.58 on 2025-09-02, reducing his holdings by 6.0% to 197,484 shares. The transaction occurred as AKRO stock trades 23.5% below its 52-week high and has declined 11.2% over the past 30 days, suggesting sales into a weaker price environment. At the same ticker (AKRO), Young's prior 5 trades show mixed timing outcomes: his 2025-03-04 sales occurred before modest 90-day gains (+14.9%, +12.6%), while his 2025-02-03 sale preceded an 18-month-plus decline. The company reported negative net income of $70,505,000.00 for its most recent full fiscal year, indicating ongoing unprofitability. The divergence between the insider's cross-ticker track record (37.50% well-timed rate) and his AKRO-specific performance (20% well-timed rate on the 5 prior measurable sales) suggests limited predictive value of this individual's selling pattern at this stock.

COO Jonathan Young sold 12,500 AKRO shares for $597,325.95 on 2025-08-12 at blended avg $47.79

Jonathan Young, Chief Operating Officer of Akero Therapeutics, executed 2 separate sales totaling 12,500 shares (12.5K shares) for $597,325.95 at an average price of $47.79 on 2025-08-12, reducing his holdings by 6.0% to 197,484 shares (197.5K shares). The transaction occurred near the 52-week high—the current stock price of $48.31 is only 16.1% below the high of $57.56—but has declined 8.4% over the past 30 days despite a 90-day gain of 20.9%. Young's prior trade history at AKRO shows mixed timing outcomes: of his 5 prior sales at this ticker, only 2 were well-timed (the stock subsequently fell), while his cross-ticker track record across all tickers yields a 90-day well-timed rate of 37.50%, below the accuracy threshold that would indicate systematic skill. The company remains unprofitable with net income of -$70,505,000.00 ($-70.5M) over its most recent full fiscal year, adding fundamental context to the market environment in which this sale occurred.

COO Jonathan Young sells 50,000 AKRO shares ($2.2M) at $44.86 avg; stock now -21.6% from 52-week high

Jonathan Young, Chief Operating Officer, executed 2 separate sales totaling 50,000 shares for $2,243,213.36 on 2025-03-04, reducing his holdings by 19.9% from 251.1K to 201.1K shares. The blended average price of $44.86 sits between the two transaction prices ($44.17 and $45.07), while the current price is $45.13—barely above the execution level. Notably, AKRO is unprofitable ($-72.7M net income) and trading 21.6% below its 52-week high despite a 90-day rally of +52.0%; this recent strength comes after significant weakness, with the stock down 16.2% over 30 days. Across his same-ticker history, Young's prior 5 sales at AKRO show mixed post-sale performance: three November trades were followed by strong 90-day gains (68.1%–77.1%), while two February sales show 30-day losses (-15.8%, -16.5%) with 90-day outcomes not yet measurable. The timing pattern across same-ticker trades is 0 of 3 well-timed at the 90-day mark, suggesting his prior exits here have not capitalized on subsequent declines.

COO Jonathan Young sold 10,000 shares of AKRO for $538,060.80 on 2025-02-03; stock at $57.56, up 108.2% in 30 days.

Jonathan Young, Chief Operating Officer of Akero Therapeutics, sold 10,000 shares (10.0K shares) in two separate transactions on 2025-02-03 for a combined $538,060.80 at a blended average price of $53.81, reducing his holdings by 3.8% to 251,147 shares. The timing of this sale coincides with exceptional recent price momentum: the stock has risen 108.2% over the prior 30 days and 65.1% over 90 days, reaching its 52-week high of $57.56. Notably, Young's prior sales at this ticker have shown a poor track record on the 90-day horizon, with 3 of 4 recent sales (November 2024) followed by further gains of +68.1% to +77.1%, suggesting his prior exit points were premature relative to subsequent rallies. The company remains unprofitable with net income of $-72,705,000.00 over its most recent fiscal year, yet the market capitalization of $4,017,638,958.88 reflects substantial investor optimism.

COO Young Jonathan sells 50,716 shares for $1.6M at AKRO as stock nears 52-week high of $32.74

Jonathan Young, COO of Akero Therapeutics, executed 3 separate sales totaling 50,716 shares for $1,601,251.55 on 2024-11-01, reducing his holdings by 19.0% from 267,002 to 216,286 shares. The sales occurred at prices ranging from $31.25 to $32.94, with a blended average of $31.57, near the current price of $32.74 which matches the 52-week high. Over 30 days the stock gained 15.9%, and over 90 days it gained 38.3%, reflecting a significant rally. Notably, this follows a prior sale at AKRO on 2024-10-14 within the same month, indicating consecutive open-market dispositions. The company remains unprofitable with net income of $-55,987,000.00 in its most recent full fiscal year, creating a backdrop where insider selling at elevated price levels warrants monitoring.

COO Jonathan Young sells 40,000 AKRO shares at $30.15; stock up 16.0% in 30 days, company unprofitable ($-56.0M net income).

Jonathan Young, Chief Operating Officer, sold 40,000 shares (representing a reduction of 15.0% of his pre-transaction holdings) on 2024-10-14 at $30.15 per share, totaling $1,206,080.00. The sale occurred during a period of strong near-term momentum—the stock has risen 16.0% over the prior 30 days and 14.7% over the prior 90 days, putting the current price of $31.05 within 0.4% of the 52-week high. However, this execution coincides with a fundamental backdrop of continued unprofitability: the company reported net income of $-56.0M over its most recent full fiscal year. The timing of a significant insider equity reduction amid a run-up in price warrants investor attention to whether the COO's exit reflects a view of current valuation relative to operational realities.